Durvalumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a phase II trial of durvalumab in combination of platinum-based chemotherapy.
Patients with stage IV Non-Small-Cell-Lung Cancer (NSCLC) with human immunodeficiency virus
(HIV) infection (cohort 1) or hepatitis B virus (HBV), or hepatitis C virus (HCV) infection
(cohort 2) will be eligible. Patients will receive standard platinum-based chemotherapy plus
durvalumab for 4 cycles (every 3 weeks), followed by durvalumab (with or without pemetrexed
for non-squamous NSCLC) maintenance therapy. We hypothesized that Durvalumab in combination
with standard chemotherapy is safe and effective for the treatment of stage IV NSCLC in
patients with HIV, HBV, or HCV infection.